

Richard L Bennett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2511074/publications.pdf>

Version: 2024-02-01

22
papers

832
citations

623734

14
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1494
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Epigenetics in Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 187-207.	9.4	185
2	The Role of Nuclear Receptor- ϵ -Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026708.	6.2	122
3	RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. <i>Blood</i> , 2006, 108, 821-829.	1.4	74
4	A Mutation in Histone H2B Represents a New Class of Oncogenic Driver. <i>Cancer Discovery</i> , 2019, 9, 1438-1451.	9.4	65
5	c-Myc and Caspase-2 Are Involved in Activating Bax during Cytotoxic Drug-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2008, 283, 14490-14496.	3.4	55
6	Serine 18 Phosphorylation of RAX, the PKR Activator, Is Required for PKR Activation and Consequent Translation Inhibition. <i>Journal of Biological Chemistry</i> , 2004, 279, 42687-42693.	3.4	53
7	The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G ₁ arrest. <i>Cell Cycle</i> , 2012, 11, 407-417.	2.6	40
8	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. <i>Oncogene</i> , 2019, 38, 671-686.	5.9	39
9	PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. <i>Blood</i> , 2013, 121, 3364-3374.	1.4	30
10	PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. <i>Blood</i> , 2015, 126, 1585-1594.	1.4	26
11	RAX is required for fly neuronal development and mouse embryogenesis. <i>Mechanisms of Development</i> , 2008, 125, 777-785.	1.7	24
12	Leveraging epigenetics to enhance the efficacy of immunotherapy. <i>Clinical Epigenetics</i> , 2021, 13, 115.	4.1	24
13	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2022, 12, 186-203.	9.4	17
14	PKR Inhibits Hematopoietic Stem Cell Differentiation. <i>Blood</i> , 2015, 126, 2443-2443.	1.4	17
15	Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding. <i>Journal of Biological Chemistry</i> , 2019, 294, 12459-12471.	3.4	16
16	Increased Expression of the dsRNA-Activated Protein Kinase PKR in Breast Cancer Promotes Sensitivity to Doxorubicin. <i>PLoS ONE</i> , 2012, 7, e46040.	2.5	15
17	Progressive Genomic Instability in the Nup98-HoxD13 Model of MDS Correlates with Loss of the PIG-A Gene Product. <i>Neoplasia</i> , 2014, 16, 627-633.	5.3	10
18	Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. <i>FASEB Journal</i> , 2017, 31, 482-490.	0.5	9

#	ARTICLE	IF	CITATIONS
19	Targeting epigenetic mechanisms to overcome venetoclax resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119047.	4.1	7
20	<i>Epigenetic Therapy.</i> , 2018, , 1-1.		2
21	RAX Activates Tumor Suppressor p53.. <i>Blood</i> , 2006, 108, 1449-1449.	1.4	1
22	The epigenetic underpinnings of lower back pain. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	1